In prostate cancer, a key therapeutic area for Bayer, new patient-relevant data from the ARASENS Phase III study in metastatic hormone-sensitive prostate cancer (mHSPC) will be showcased, as well as data from the RALU study comprising real-world evidence with radium-223 dichloride as a prior treatment to 177Lu-PSMA for patients with metastatic castration-resistant prostate cancer (mCRPC) / On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors (also known as TRK fusion cancers) / New data evaluating regorafenib in various cancers will also be featured
1360MO, 1392P, 1394P, 464P, 463P, 1209P, 400P
Bayer will present crucial scientific exploration in oncology at the forthcoming ESMO Congress 2022 from September 9- 13, 2022. Data will punctuate Bayer’s commitment to advancing unmet requirements in prostate cancer, furnishing moxie in perfection drug, and working on immunotherapy combinations, including company- patronized and cooperative exploration studies.
New Phase III ARASENS trial data for darolutamide will be presented on quality of life and case-applicable endpoints in those living with metastatic hormone-sensitive prostate cancer( mHSPC). Darolutamide is an androgen receptor asset( ARi) approved under the brand name Nubeqa ™ in further than 70 countries around the world, including theU.S., European Union( EU), Japan, and China, for the treatment of cases withnon-metastatic castration- resistant prostate cancer( nmCRPC) who are at high threat of developing metastatic complaint. Bayer lately enteredU.S. Food and Drug Administration( FDA) blessing for darolutamide in combination with docetaxel in mHSPC and submitted operations for darolutamide in combination with docetaxel in mHSPC to the European Medicine Agency( EMA), the Ministry of Health, Labor, and Welfare( MHLW) in Japan, and China’s Center of medicine Evaluation( CDE). Darolutamide is developed concertedly by Bayer and Orion Corporation, a encyclopedically operating Finnish pharmaceutical company.
Also, data from the RALU study with radium- 223 dichloride will be presented, which includes safety and effectiveness issues in cases with metastatic castration- resistant prostate cancer( mCRPC) entering lutetium-177-prostate-specific membrane antigen( 177Lu- PSMA) after radium- 223 dichloride. This data not only focuses on the treatment sequence of radium- 223 dichloride followed by 177Lu- PSMA, but also includes data on the feasibility of adding docetaxel in the treatment pathway. Data from the REASSURE study will also be featured, showing the value of the biomarker alkaline phosphatase( peak) for assessing treatment response with radium- 223 dichloride. Radium- 223 dichloride, approved under the brand name Xofigo ™, is indicated for the treatment of cases with mCRPC, characteristic bone metastases, and no given visceral metastatic complaint, in progression after at least two previous lines of systemic remedy for mCRPC( other than LHRH analogues), or ineligible for any available systemic mCRPC treatment
Other investigational data pressing regorafenib, approved under the brand name Stivarga ™, in intermittent or metastatic solid excrescences and in regressed refractory metastatic colorectal cancer( mCRC) will also be presented at the congress.
Details on notable donations from Bayer for the ESMO Congress 2022 are listed below
· Quality of life and case-applicable endpoints with darolutamide in the phase 3 ARASENS study
o Oral donation 1360MO; September 11
Radium- 223 dichloride( Ra- 223)
· Lutetium-177-Prostate-Specific Membrane Antigen remedy( 177Lu- PSMA) in Cases( Pts) with previous Radium- 223( 223Ra) Safety and Effectiveness issues
oE-Poster 1392P; September 11
· Alkaline Phosphatase( peak) Decline and Pain Response as Labels for Overall Survival( zilches) in Cases( Pts) with Metastatic Castration- Resistant Prostate Cancer( mCRPC) Treated with Radium- 223( 223Ra) in the REASSURE Study
oE-Poster 1394P; September 11
·Intra-Patient( Pt) Comparison From Larotrectinib( Laro) Clinical Trials in Tropomyosin Receptor Kinase( TRK) Fusion Cancer- an Expanded Dataset
oE-Poster 464P; September 12
· efficacity and Safety of Larotrectinib in a Pooled Analysis of Cases( Pts) With Tropomyosin Receptor Kinase( TRK) Fusion Cancer With an Extended Follow- Up
oE-Poster 463P; September 12
· A phase II study of regorafenib in combination with nivolumab in cases with intermittent or metastatic solid excrescences Results from the esophageal scaled cell melanoma( ESCC) cohort
oE-Poster 1209P; September 12
· Impact of regorafenib cure optimization on relative issues in the treatment of regressed refractory metastatic colorectal cancer( mCRC)
oE-Poster 400P; September 11
About Oncology at Bayer
Bayer is committed to delivering wisdom for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop innovative drugs that help ameliorate and extend the lives of people living with cancer. The oncology ballot at Bayer includes six retailed products across colorful suggestions and several composites in different stages of clinical development. Bayer focuses its exploration conditioning on first- in- class inventions across the following scientific platforms Precision Molecular Oncology, Targeted nascence curatives, and Immuno- Oncology. Across the areas of focus, we’ve several prostate cancer treatments on the request or in development, with the thing of extending survival while limiting side goods of treatment throughout the different stages of the complaint. Another crucial focus at Bayer is on innovative perfection oncology treatments, with an approved TRK asset simply designed to treat excrescences that have an NTRK gene emulsion, the oncogenic motorist of excrescence growth and spread. The company’s approach to exploration prioritizes targets and pathways with the eventuality to impact the way that cancer is treated.
Bayer is a global enterprise with core capabilities in the life wisdom fields of health care and nutrition. Its products and services are designed to help people and the earth thrive by supporting sweats to master the major challenges presented by a growing and growing global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and produce value through invention and growth. The Bayer brand stands for trust, trustability and quality throughout the world. In financial 2021, the Group employed around,000 people and had deals of44.1 billion euros.